Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00240929 | A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis) | PHASE2 | COMPLETED | 150 | — | — | Sep 1, 2002 | Apr 1, 2003 | Nov 15, 2010 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| MEDI-493 | DRUG | Active Comparator |
Inclusion Criteria: * The child must have been born at greater than or equal to 35 weeks gestation and be greater than or equal to 6 months of age at the time of randomization (child must be randomized on or before their 6-month birthday) * The child's parent or legal guardian must provide written ...